Alembic Pharma Receives USFDA Approval for Valganciclovir Oral Solution
Alembic Pharmaceuticals receives USFDA final approval for Valganciclovir for Oral Solution, marking its 247th ANDA approval and strengthening its US portfolio.
Pharmaceuticals
Latest Pharmaceuticals stock news from NSE and BSE filings, 95 stories so far.
Financial Results
OneSource Specialty Pharma Q2 Net Profit Jumps 448% YoY to ₹57.5 Crore as Margins Expand
OneSource Specialty Pharma reports a 448% YoY surge in net profit to ₹57.5 crore for Q2 FY27, with operating margins climbing to 10.2% and revenue up 37% YoY.
Financial Results
Mankind Pharma Q2 Results: Net Profit Surges 37.7% YoY to ₹716 Crore as Margins Expand
Mankind Pharma reports a 37.7% YoY rise in Q2 FY27 net profit to ₹716 crore, with operating margins expanding to 21% and revenue reaching ₹4,338 crore.
Partnership
Orchid Pharma Inks USD 80 Million Latin American Licensing Deal for Exblifep
Orchid Pharma enters a licensing deal with Laboratorio Libra for Exblifep in Latin America, representing a potential USD 80 million opportunity over 10 years.
Promoter Buying
Granules India Promoters Inject ₹1,096 Crore Via Conversion of 2.49 Crore Warrants
Granules India allotted 2.49 crore equity shares to promoter group members upon warrant conversion, involving a balance payment of ₹1,096.13 crore on October 23.
Fund Raise
Fredun Pharmaceuticals Allots 44,000 Equity Shares Following Warrant Conversion
Fredun Pharmaceuticals allotted 44,000 equity shares to non-promoters after converting 14,667 warrants, adjusted for a bonus issue at a 3:1 ratio in October 2026.
Partnership
Zydus Lifesciences Division Zylidac Bio Partners to Scale Prolific Machines Technology
Zydus Lifesciences' Zylidac Bio partners with Prolific Machines to scale light-controlled biologics manufacturing. Latest quarterly revenue stands at ₹8,017 Cr.
Regulatory Approval
Zydus Lifesciences Secures USFDA Approval for Menopause Patch with 180-Day Exclusivity
Zydus Lifesciences receives USFDA approval for Estradiol and Levonorgestrel Transdermal System, targeting a USD 45.7 million US market with 180-day exclusivity.
Regulatory Approval
Dr. Reddy's Zytorvi Secures DCGI Approval for Advanced Esophageal Cancer Treatment
Dr. Reddy's Laboratories receives DCGI approval for Zytorvi for advanced esophageal cancer treatment in India. The drug reduced death risk by 42% in trials.
Financial Results
Aptus Pharma H1 Results: Net Profit Surges 200% to ₹5.1 Crore as Revenue Hits ₹48.9 Crore
Aptus Pharma reports H1-27 net profit growth of 200% YoY to ₹5.1 crore. Revenue from operations climbed to ₹48.9 crore as the company expands its national footprint.
Fund Raise
Orchid Pharma Board Approves ₹600 Crore Fundraise for Strategic Growth
Orchid Pharma Ltd's board has approved an enabling resolution to raise up to ₹600 crore through equity or debt, representing 11.2% of its current market cap.
Earning Call
Bajaj Healthcare Q2 Revenue Grows 18.9% to ₹175.9 Crore Driven by Formulations
Bajaj Healthcare reports Q2 FY27 revenue of ₹175.9 Cr, up 18.9% YoY. Formulations jump 82% as the company targets ₹1000 Cr revenue by FY29 and expands capacity.
Product Launched
Natco Pharma Launches Carboplatin Injection in U.S. to Address Critical Drug Shortage
Natco Pharma launches Carboplatin Injection, a generic Paraplatin®, in the U.S. market to address critical shortages. Market size estimated at USD 27.8 million.
Regulatory Approval
Alembic Pharmaceuticals Secures USFDA Approval for Otic Suspension Targeting $110 Million Market
Alembic Pharmaceuticals receives USFDA final approval for Ciprofloxacin and Dexamethasone Otic Suspension, addressing a US$110 million market as of June 2026.
Regulatory Approval
Venus Remedies Secures 5 New Global Drug Approvals Across 4 International Markets
Venus Remedies (VENUSREM) gains five drug approvals in Kazakhstan, Peru, Kuwait, and Argentina. Expanding its global reach after a 139% YoY profit surge in Q1.
Financial Results
Solara Active Pharma Reports ₹28.5 Crore Q2 Profit as Operating Margins Rise to 6.8%
Solara Active Pharma Sciences Limited reports a Q2-27 net profit of ₹28.5 crore, a significant turnaround from a loss of ₹10.1 crore in the year-ago period.
Regulatory Approval
Zim Laboratories Secures Australia TGA GMP Certification for Nagpur Manufacturing Facility
Zim Laboratories received TGA GMP certification for its Nagpur facility, covering various dosage forms until 2028, boosting its presence in the Australian market.
Financial Results
Accent Microcell Reports 72% Profit Growth in H1-27 as Operating Margins Expand to 23.3%
Accent Microcell reports H1-27 net profit of ₹31.1 crore, a 71.8% year-on-year increase, alongside expanding operating margins of 23.3% in pharmaceuticals.
